Recent research suggests that lesser-known cannabinoids derived from marijuana and hemp, such as CBN, CBM, CBC, CBDV and THCV, might hold promise in treating dermatological conditions INCLUDING acne, psoriasis and eczema. The study, published recently in the peer-reviewed journal “Molecules,” highlights the potential therapeutic value of these minor cannabinoids in managing skin disorders as well as presenting new avenues for patient care and well-being enhancement.

The research, led by Polish scholars Dorota Kowalczuk and Emilia Kwiecień, involved an extensive review of existing scientific literature. The team observed that minor cannabinoids exhibit a range of pharmacological activities, encompassing anti-itch, analgesic, antimicrobial and anti-inflammatory properties. These cannabinoids have also shown efficacy in alleviating symptoms linked to various dermatological issues, including pruritus, acne, eczema and psoriasis.

Some minor cannabinoids appeared particularly suited for targeting specific skin conditions. For instance, CBDV, due to its anti-inflammatory characteristics, can potentially soothe itching and inflammation related to atopic dermatitis. Additionally, its antioxidant properties could aid in healing acne lesions.

Similarly, other recently identified cannabinoids such as CBE and CBM display anti-inflammatory potential and open new avenues for research into targeted disease conditions. CBC, known for its anti-inflammatory and antioxidant effects, may offer benefits for treating psoriasis, acne and atopic dermatitis.

THCV stands out for its potential in combating acne because it appears to regulate sebum production. Its anti-inflammatory and antibacterial attributes contribute to alleviating inflammation and targeting bacteria linked to acne development.

The researchers highlighted the therapeutic potential of minor cannabinoids, including cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), tetrahydrocannabivarin (THCV), cannabichromene (CBC), cannabidiforol (CBDP) and cannabidivarin (CBDV), as well as newer discoveries such as cannabielsoin (CBE) and cannabimovone (CBM).

The effects are believed to stem from interactions between cannabinoids and the body’s endocannabinoid system, a central regulatory mechanism crucial for maintaining organism health and function. This system plays a pivotal role in regulating skin functions, immune responses, cell differentiation, proliferation and survival, thereby effectively mitigating skin inflammation. Furthermore, topical application of these minor cannabinoids may hold promise for mitigating aging-related effects on the skin.

However, the researchers caution that more in-depth research is essential to validate their safety and effectiveness. Multiple challenges, including impact on the nervous system, product quality and regulation concerns, and ethical and legal considerations, need comprehensive exploration.

They concluded that despite the encouraging therapeutic potential, the utilization of cannabinoids, particularly minor ones, requires continued research, stringent regulations and a balanced approach to maximize benefits while minimizing any potential risks to health and society.

Companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) selling marijuana for both medical and recreational use could be helping people combat more symptoms or conditions than the patients themselves intend.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Last week, the governor of California signed into law a reform that opens the state’s economy globally to manufacturers of hemp-derived CBD products. The bill the governor signed, dubbed AB45, creates a framework for the manufacture and sale of hemp-derived products in the state.

The measure will allow hemp-derived CBD products to be sold to the state’s adult-use or medical cannabis retailers, with forecasts showing that those stores will hit sales of between $4.8 billion and $5.7 billion this year. Canopy Growth Corp.’s (TSX: WEED) (NASDAQ: CGC) head of lobbying, David Culver, states that officials had been working on this measure for more than two years.

Canopy Growth is involved in the manufacture of CBD products derived from hemp, which include a line of CBD gummies and Biosteel sports drinks. However, the company hasn’t been selling those products in California because the state’s cannabis policy didn’t allow the sale of over-the-counter CBD products.

In an interview, Culver stated that the measure would open up the state’s market and offer regulatory certainty for retailers in California to assure them that their products for sale won’t be confiscated or seized. Back in 2018, a ban on hemp-derived CBD in drinks and dietary supplements and food led to product seizures and occasional raids.

CV Sciences senior vice president of scientific and regulatory affairs Doug MacKay stated that before the 2018 ban, the company had been operating successfully in California and had built a lot of relationships. CV Sciences is involved in the manufacture and sale of hemp-derived CBD products. It sells its products in CVS drugstores and other countrywide retailers. After the ban, the company, which is based in California, had to stop distributing its products in brick-and-mortar shelves in the state.

MacKay applauds cannabis and hemp negotiators for not giving up until a compromise for the sale of CBD products was reached. In his statement, he noted that the measure marked a clear pathway to the market and afforded retailers a clear way to work with other CBD companies that are willing to have the right labeling and follow the laws.

However, not everyone is happy with the measure, as the ban on smokable hemp is still intact, which leaves hemp farmers at a disadvantage. National Industrial Hemp Council spokesperson Larry Farnsworth stated that the measure would affect hemp farmers in the state who grow smokable hemp flower. Some hemp producers in the state have even threatened to file a lawsuit over the new measure.

Those grumbles notwithstanding, the passing of the CBD law in California is likely to broaden the market for leading manufacturers of CBD products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

When you think of the stock market, the last thing you probably think of is cannabis and marijuana. However, you would be mistaken to discount this booming industry, the marijuana industry is expected to triple in the next five years.

As states and entire countries decriminalize or legalize cannabis and/or its components, there are loads of opportunities for entrepreneurs and existing companies.

But as in any nascent industry, there are also loads of risks and bad actors. Whether you’re a first-time investor or a seasoned veteran, it pays to understand all of the moving parts.

This guide will get you up to speed and give you a list of the top 5 cannabis stocks to watch in 2020.

As Cannabis, or most popularly one type of cannabis namely marijuana, has become increasingly more popular and even legal in some parts of the world, multiple public companies have emerged which provide individuals and institutions opportunities to invest in this new product and make a potential profit. This article will discuss a top 5 list of cannabis stocks to look at in 2020.

Why Cannabis Stocks?

Before discussing the top 5 Cannabis stocks to watch in 2020, we will first list a few reasons why cannabis stocks may be your next best investment:

1. The demand of cannabis-containing products is increasing. As stated in the introduction of this article, a lot of new products are arising and ever more importantly. Cannabis is being legalized and classified as essential in some medical treatments across a variety of countries. This will, of course, increase the demand and usage of these products, bringing growth to investors.
2. Cannabis stocks are currently undervalued. If we are certain that this new product will be successful in the future, it is a no-brainer to start investing and buying stocks now while they are so cheap.
3. A lot of these companies still have huge upside potential. At the current moment in time, they are struggling to stay profitable as demand is still quite low, but as soon as the rest of the world catches onto this product, huge potential could be fulfilled and early investors could reap the rewards.

The top 5 companies listed below have been chosen due to their international presence and market capitalization.

1. Canopy Growth

Canopy Growth Corporation (TSX: WEED, NYSE: CGC) is the largest cannabis stock at the moment with a market cap of $6.99 Billion. This stock can be traded on the NYSE and is currently traded at 21.22 CAD ($14.99 USD) as of April 2020. Canopy Growth shows a great business plan and profit-gaining strategy.

2. GW Pharmaceuticals

GWPH has previously stated that they do not want to be seen as part of the “marijuana stock” group, but this cannot be hidden as they are currently have a market cap of $3.21 billion. This stock can currently be traded on NASDAQ and currently trades at 105.76 USD.

3. Curaleaf Holdings

Curaleaf is the largest multistate operator in the United States, bragging with a market cap of $2.75 billion. The company is public and their stocks can be traded on OTC under CURLF. The price of one stock in this company is $5.76 CAD, which is equal to $4.07 USD.

4. Cronos Group

The Cronos Group currently has a market cap of $2.3 billion and sells their stocks at 8.37 CAD ($5.91) under CRON. Although Cronos group is not such a big producer as the rest of the candidates in this top 5, its market cap is aided dramatically by investors, which may be a good indication of its success, or not.

5. Aurora Cannabis

The 5th and final cannabis stock we are going to list in this article is Aurora Cannabis. Aurora Cannabis currently has a market cap of $2.15 billion and sells stocks publicly on the NYSE under ACB. Aurora was stated to be the largest pot producer and even have a bigger international capacity than the top competitor Canopy Growth. Aurora stocks currently sell for $0.72.

Conclusion

In conclusion to this article, we hope that you as an individual now have a better overview of some popular cannabis stocks available. We hope that you can see the value in early investing and trust this list has given you some stocks to research when looking to possible add to your stock market portfolio.

– This article was provided by Mitchell Roach, the founder of StartTrading, and published by CannabisNewsWire (CNW).

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

This article contains Third-Party Content submitted by third parties, including articles submitted through the CNW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of CNW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and CNW does not endorse, guarantee or make representations concerning the accuracy and completeness of all third-party content. You acknowledge that by CNW providing you with this internet portal that makes accessible to you the ability to view third-party content through the CNW site, CNW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. CNW expressly disclaims liability relating to such third-party content. CNW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, CNW reserves the right to remove third-party content at any time in its sole discretion.